Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
Open Access
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- CD39 and CD73 in immunity and inflammationTrends in Molecular Medicine, 2013
- Akt and mTOR in B Cell Activation and DifferentiationFrontiers in Immunology, 2012
- A Subset of Interleukin-21+ Chemokine Receptor CCR9+ T Helper Cells Target Accessory Organs of the Digestive System in AutoimmunityImmunity, 2011
- Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept studyAnnals of the Rheumatic Diseases, 2008
- RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent TranslationJournal of Biological Chemistry, 2007
- Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosusArthritis & Rheumatism, 2006
- Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndromeArthritis & Rheumatism, 2002
- Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR ActionCell, 2002
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002